This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Calvo, B. F. Articles by Mohler, J. L. Search for Related Content PubMed PubMed Citation Articles by Calvo, B. F. Articles by Mohler, J. L.

Human Epidermal Receptor-2 Expression in Prostate Cancer¹

Department of Surgery, Divisions of Surgical Oncology [B. F. C.] and Urology [A. M. L., M. M., Q. F. C., C. W. G., J. L. M.], Department of Pathology and Laboratory Medicine [M. V. I., J. L. M.], Department of Pediatrics, Laboratories for Reproductive Biology [C. W. G.], Department of Medicine, Division of Hematology/Oncology [Y. E. W.], and the University of North Carolina–Lineberger Comprehensive Cancer Center [B. F. C., L. S. C., Y. L., Y. E. W., H. S. E., J. L. M.], University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599

Purpose: Efforts to conclusively establish that human epidermal receptor (HER)-2 overexpression is important to androgen-dependent carcinoma of the prostate (AD-CaP) or to progression to androgen independence (AI-CaP) have failed because of variability in tissue procurement, antibodies, immunostaining procedures, and assessment methods. However, because some in vitro and animal model data correlate HER-2 overexpression with progression to androgen independence, trials of agents that target the HER-2 receptor are under way. To clarify human tumor findings, we studied HER-2 expression at the gene (DNA), mRNA, and protein levels in well-characterized CaP specimens.

Experimental Design: Fifty AD-CaP and 25 AI-CaP specimens from similar numbers of Caucasian and African Americans were immunostained for HER-2 receptor. HER-2 mRNA levels were measured using real-time fluorescence quantitative PCR in patients for whom frozen specimens were available. HER-2 amplification was evaluated using fluorescent in situ hybridization.

Results: HER-2 receptor immunostained in 52% of androgen-dependent and one (4%) androgen-independent tumor. HER-2 immunostaining was not related to age, race, serum prostate-specific antigen levels, or pathologic stage and Gleason grade. HER-2 overexpression was not detected in AI-CaP at the mRNA or gene level. Mean HER-2 mRNA expression was higher (P < 0.05) in AD-CaP than AI-CaP (22,080 versus 15,496 HER-2 copies). HER-2 was not amplified in any of 20 AD-CaP or 19 AI-CaP specimens.

Conclusions: HER-2 protein and message overexpression and HER-2 amplification were not found in AI-CaP.

This article has been cited by other articles:

				J. S. de Bono, J. Bellmunt, G. Attard, J. P. Droz, K. Miller, A. Flechon, C. Sternberg, C. Parker, G. Zugmaier, V. Hersberger-Gimenez, et al. Open-Label Phase II Study Evaluating the Efficacy and Safety of Two Doses of Pertuzumab in Castrate Chemotherapy-Naive Patients With Hormone-Refractory Prostate Cancer J. Clin. Oncol., January 20, 2007; 25(3): 257 - 262. [Abstract] [Full Text] [PDF]

				Z. Li, M. Szabolcs, J. D. Terwilliger, and A. Efstratiadis Prostatic intraepithelial neoplasia and adenocarcinoma in mice expressing a probasin-Neu oncogenic transgene Carcinogenesis, May 1, 2006; 27(5): 1054 - 1067. [Abstract] [Full Text] [PDF]

				I. H. Koumakpayi, J.-S. Diallo, C. Le Page, L. Lessard, M. Gleave, L. R. Begin, A.-M. Mes-Masson, and F. Saad Expression and Nuclear Localization of ErbB3 in Prostate Cancer. Clin. Cancer Res., May 1, 2006; 12(9): 2730 - 2737. [Abstract] [Full Text] [PDF]

				L. Chen, S. Meng, H. Wang, P. Bali, W. Bai, B. Li, P. Atadja, K. N. Bhalla, and J. Wu Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824 Mol. Cancer Ther., September 1, 2005; 4(9): 1311 - 1319. [Abstract] [Full Text] [PDF]

				C Hughes, A Murphy, C Martin, O Sheils, and J O'Leary Molecular pathology of prostate cancer J. Clin. Pathol., July 1, 2005; 58(7): 673 - 684. [Abstract] [Full Text] [PDF]

				Y. Liu, S. Majumder, W. McCall, C. I. Sartor, J. L. Mohler, C. W. Gregory, H. S. Earp, and Y. E. Whang Inhibition of HER-2/neu Kinase Impairs Androgen Receptor Recruitment to the Androgen Responsive Enhancer Cancer Res., April 15, 2005; 65(8): 3404 - 3409. [Abstract] [Full Text] [PDF]

				C. W. Gregory, Y. E. Whang, W. McCall, X. Fei, Y. Liu, L. A. Ponguta, F. S. French, E. M. Wilson, and H. S. Earp III Heregulin-Induced Activation of HER2 and HER3 Increases Androgen Receptor Transactivation and CWR-R1 Human Recurrent Prostate Cancer Cell Growth Clin. Cancer Res., March 1, 2005; 11(5): 1704 - 1712. [Abstract] [Full Text] [PDF]

				J. Carles, J. Lloreta, M. Salido, A. Font, M. Suarez, V. Baena, M. Nogue, M. Domenech, and X. Fabregat Her-2/neu Expression in Prostate Cancer: A Dynamic Process? Clin. Cancer Res., July 15, 2004; 10(14): 4742 - 4745. [Abstract] [Full Text] [PDF]

				C. W. Gregory, X. Fei, L. A. Ponguta, B. He, H. M. Bill, F. S. French, and E. M. Wilson Epidermal Growth Factor Increases Coactivation of the Androgen Receptor in Recurrent Prostate Cancer J. Biol. Chem., February 20, 2004; 279(8): 7119 - 7130. [Abstract] [Full Text] [PDF]

				Y. Daaka G Proteins in Cancer: The Prostate Cancer Paradigm Sci. Signal., January 20, 2004; 2004(216): re2 - re2. [Abstract] [Full Text] [PDF]

				A. L. Bookout, A. E. Finney, R. Guo, K. Peppel, W. J. Koch, and Y. Daaka Targeting G{beta}{gamma} Signaling to Inhibit Prostate Tumor Formation and Growth J. Biol. Chem., September 26, 2003; 278(39): 37569 - 37573. [Abstract] [Full Text] [PDF]